Nimotuzumab
2018-FXY-206
Phase 3 small_molecule active
Quick answer
Nimotuzumab for Nasopharyngeal Carcinoma is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active